Endoscopy-negative reflux disease

被引:22
作者
Carlsson, R [1 ]
Holloway, RH
机构
[1] AstraZeneca R&D, Clin Sci, S-43183 Molndal, Sweden
[2] Royal Adelaide Hosp, Dept Gastroenterol Hepatol & Gen Med, Adelaide, SA 5000, Australia
关键词
endoscopy-negative; epithelial dysfunction; gastro-oesophageal reflux disease; heartburn; oesophageal pH; quality of life;
D O I
10.1053/bega.2000.0127
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The majority of patients with symptoms of gastro-oesophageal reflux have no endoscopic evidence of oesophagitis. There has been remarkably little systematic gathering of information about this group of patients. It is commonly believed that they have a mild form of reflux disease, with low levels of dysfunction that usually respond to simple therapeutic measures. Emerging data from recent studies indicate that this is not the case. Endoscopy-negative patients have symptom severities comparable to those with erosive disease, and which significantly impair their quality of life. The limited data available on the pathophysiology of endoscopy-negative reflux disease suggest that, in the majority of patients, it is as much a disease of excessive gastro-oesophageal reflux as it is in patients with oesophageal lesions. The same principles that apply to successful treatment in patients with oesophagitis also hold true for patients with endoscopy-negative disease.
引用
收藏
页码:827 / 837
页数:11
相关论文
共 50 条
[1]   Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis [J].
Bate, CM ;
Green, JRB ;
Axon, ATR ;
Murray, FE ;
Tildesley, G ;
Emmas, CE ;
Taylor, MD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (04) :755-763
[2]  
BEHAR J, 1976, GASTROENTEROLOGY, V71, P9
[3]   Is the esophageal squamous epithelial barrier function impaired in patients with gastroesophageal reflux disease? [J].
Carlsson, R ;
Fändriks, L ;
Jönsson, C ;
Lundell, L ;
Orlando, RC .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1999, 34 (05) :454-458
[4]  
Carlsson R, 1998, SCAND J GASTROENTERO, V33, P1023
[5]   Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole [J].
Carlsson, R ;
Dent, J ;
Watts, R ;
Riley, S ;
Sheikh, R ;
Hatlebakk, J ;
Haug, K ;
de Groot, G ;
van Oudvorst, A ;
Dalvag, A ;
Junghard, O ;
Wiklund, I .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (02) :119-124
[6]   ENDOSCOPIC MEASUREMENT OF ESOPHAGEAL TRANSMUCOSAL POTENTIAL DIFFERENCE IN REFLUX ESOPHAGITIS [J].
COLLINS, BJ ;
MCFARLAND, RJ ;
SLOAN, JM ;
LOVE, AHG .
GUT, 1984, 25 (10) :1103-1106
[7]   An evidence-based appraisal of reflux disease management - the Genval workshop report [J].
Dent, J ;
Brun, J ;
Fendrick, AM ;
Fennerty, MB ;
Janssens, J ;
Kahrilas, PJ ;
Lauritsen, K ;
Reynolds, JC ;
Shaw, M ;
Talley, NJ .
GUT, 1999, 44 :S1-S16
[8]   Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease [J].
Dimenas, E ;
Carlsson, G ;
Glise, H ;
Israelsson, B ;
Wiklund, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 :8-13
[9]   ESOPHAGEAL TRANSMURAL POTENTIAL DIFFERENCE IN PATIENTS WITH SYMPTOMATIC GASTRO-ESOPHAGEAL REFLUX [J].
ECKARDT, VF ;
ADAMI, B .
KLINISCHE WOCHENSCHRIFT, 1980, 58 (06) :293-297
[10]  
Fullerton SC, 1999, GASTROENTEROLOGY, V116, pA166